Meta-Analysis of the Effectiveness of Using Antiplatelet Drugs Uptake in Decreasing Mortality in COVID-19 Patients
Abstract
Background: Viscoelastic coagulation testing in COVID-19 patients often found elevated concentrations of D-dimer and fibrinogen. Thrombotic complications can be in the form of Venous Thromboembolism (VTE), where this thrombotic disease is one of the factors associated with increased mortality of COVID-19 patients. This study aims to analyze the effectiveness of antiplatelet drugs in reducing mortality in COVID-19 patients.
Subjects and Method: This is a meta-analysis study using PRISMA flowchart guidelines. The article search process was carried out between 2020-2021 using PubMed, Science Direct, Google Scholar, and Scopus databases. The article search was carried out by considering the eligibility criteria defined in the PICO model. Population= COVID-19 patients, Intervention= using antiplatelet drugs, Comparison= not using anticoagulant drugs, Outcome= mortality. The keywords used were "antiplatelet" AND "mortality" AND "COVID-19". The inclusion criteria used were English full-text cohort papers and the relationship measure used as the adjusted odds ratio (aOR). Based on the database, 9 articles fulfilled the inclusion criteria. The analysis was carried out using RevMan 5.3 software.
Results: The meta-analysis was carried out on 9 articles from the UK, Spain, Germany, Poland, America, Israel, and China. The results of data processing showed that COVID-19 patients who received antiplatelet drugs had a 0.70 times risk of dying than those without antiplatelet drugs, and it was not statistically significant (aOR= 0.70; CI 95%= 0.46 to 1.07; p= 0.100).
Conclusion: The use of anticoagulant drugs reduces the mortality risk of COVID-19 patients, but it is not statistically significant.
Keywords: antiplatelet, mortality, COVID-19
Correspondence: Happy Nurhayati. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: happyajja3@gmail.com. Phone: +62 81226160538.
Indonesian Journal of Medicine (2021), 06(03): 315-324
References
Aaronson PI, Ward JP, Connolly MJ (2013). The cardiovascular system: at a glance. 4th edn. New Jersey: Wiley Blackwell.
Abu-Jamous B, Anisimovich A, Baxter J, Mac-killop L, Vizcaychipi VP, McCarthy A, Khan RT (2020). Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data. medRxiv. 1–18.
Aghajani MH, Moradi O, Amini H, Tehrani HA, Pourheidar E, Rabiei MM, Sistanizad M (2021). Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. J. Med. Virol. 93(9): 5390–5395. doi: 10.1002/jmv.27053.
Benson RA, Nandhra S (2021). Outcomes of vascular and endovascular interventions performed during the coronavirus disease 2019 (covid-19) pandemic the vascular and endovascular research network (vern) covid-19 vascular service (cover) tier 2 study. Ann. Surg. 273(4): 630–635. doi: 10.1097/SLA.0000000000004722.
CEBMa (2014). Critical Appraisal for cross-sectional study. Amsterdam.
Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, McCurdy MT, et al. (2021). Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth. Analg. 132(4). 930–941. doi: 10.1213/ANE.000-0000000005292.
Corrochano M, Acosta-Isaac R, Mojal S, Miqueleiz S, Rodriguez D, Quijada-Manuitt MA, Fraga E, et al. (2021). Impact of preadmission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. J THROMB THROMBOLYS. Springer. 2019(012-3456789). doi: 10.1007/s11239-021-02507-2.
Diaz T, Trachtenberg BH, Abraham SJK, Sharaf RK, Durant-Archibold AA (2020). Aspirin bioactivity for prevention of cardiovascular injury in COVID-19. Front. Cardiovasc. med. 19–22. doi: 10.3389/fcvm.2020.562708.
Fröhlich GM, Jeschke E, Eichler U, Thiele H, Alhariri L, Reinthaler M, Kastrati A, et al. (2021). Impact of oral anticoagulation on clinical outcomes of COVID-19: a nation-wide cohort study of hospitalized patients in Germany. Clin Res Cardiol. 110(7): 1041-1050. doi: 10.1007/s00392-02001783-x.
Harthi AA, Sulaiman KA, Aljuhani O, Korayem GB, Altebainawi AF, Alenezi, RS, Harbi SA, et al. (2020). Evaluation of low-dose aspirin use among COVID-19 critically ill patients: A multicenter propensity score matched study. Clin Res Cardiol. 1–17.
Karruli A, Booccia F, Gagliardi M, Patauner F, Ursi MP, Sommese P, Rosa RD, et al. (2021). Multidrug-resistant infections and outcome of critically ill patients with coronavirus disease 2019: a single center experience. Microb. Drug Resist. doi: 10.1089/mdr.2020.0489.
Levani, Prastya and Mawaddatunnadila (2021). Coronavirus disease 2019 (COVID-19): patogenesis, manifestasi klinis dan pilihan terapi. Jurnal Kedokteran dan Kesehatan. 17(1): 44–57. Retrieved from https://jurnal.umj.ac.id/index.php/JKK/article/view/6340.
Liu Q, Huang N, Li A, Zhou Y, Liang L, Song Q, Yang Z, et al. (2021). Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine. 100(6):e24544. doi: 10.1097/MD.00000000000-24544.
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, et al. (2021). Intermediatedose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A pro-pensity score-matched analysis. Am. J. Hematol. 96(4): 471–479. doi: 10.1002/ajh.26102.
Merzon E, Green I, Vinker S, Golan-Cohen A, Gorohovski A, Avramovich E, Frenkel-Morgenstern M, et al. (2021). The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. FEBS Journal. 1–11. doi: 10.1111/febs.15784.
Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. (2021). Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. Signal Transduct Target Ther. 6(1). doi: 10.1038/s41392-021-00689-y.
Murti B (2018). Prinsip dan metode riset epidemiologi. Ed 5. Surakarta: Program Studi Ilmu Kesehatan Masyarakat.
Neal MJ (2015) Medical pharmacology at a glance. Eighth edition. New Jersey: Wiley Blackwell.
Osborne TF, Veigulis ZP, Arreola DM, Mahajam SM, Roosli E, Curtin CM (2021). Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS ONE. 16(02): 5–14. doi: 10.1371/journal.pone.0246825.
Rakhmawati N, Paryono, Setyaningsih I (2019). Resistensi antiplatelet pada stroke iskemik. Berkala Neurosains. 18(1): 1–7.
Retnawati H, Apino E, Kartianom, Djidu H, Anazifa RD (2018). Pengantar analisis meta Yogyakarta: Parama Publishing.
Sahai A, Bhandari R, Godwin M, McIntyre T, Chung MK, Jean-Pierre I, Kamran H, et al. (2021). Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vascular Medicine (United Kingdom). doi: 10.1177/1358863X21101-2754.
Siddaway AP, Wood AM, Hedges LV (2019). How to do a systematic review: A best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses. Annu. Rev. Psychol. 70: 747–770. doi: https://doi.org/10.1146/annurev-psych-010418-102803.
Son M, Noh M, Lee JH, Seo J, Park H, Yang S (2021). Effect of aspirin on coronavirus disease 2019. Medicine: 100(30): e26670. doi: 10.1097/md.0000000000026670.
Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan, Sinto R, et al. (2020). Coronavirus Disease 2019: Tinjauan literatur terkini. Acta Med Indones. 7(1): 45. doi: 10.7454/jpdi.v7i1.4-15.
Terlecki M, Wojciechowska W, Klocek M, Olsza-necka A, Stolarz-Skrzypek K, Grodzicki T, Małecki M, et al. (2021). Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: Data from a large single-center registry in Poland. Kardiologia Polska: 79(8): 773–780. doi: 10.33963/KP.15990
Tremblay D, Gerwen MV, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, et al. (2020). Impact of anticoagulation prior to COVID-19 infection: A propensity score-matched cohort study. Blood: 136(1): 144–147. doi: 10.1182/BLOOD.2020006941.
Yuan SH, Chen P, Li H, Chen CH, Wang F, Wang DW et al. (2021). Mortality and prehospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 25(2): 1263–1273. doi: 10.1111/jcmm.16198.
